Skip to content

The Policy Vault

Methodology Why Contact

Coverage / United Healthcare / enzalutamide / metastatic castration-sensitive prostate cancer (mCSPC)

enzalutamide — United Healthcare

metastatic castration-sensitive prostate cancer (mCSPC)

Initial criteria

Patient is less than 19 years of age

Approval duration

12 months

Provenance

View official policy PDF

Plan: United Healthcare
Drug: enzalutamide
Indication: metastatic castration-sensitive prostate cancer (mCSPC)
Last seen: 2025-10-14
Hash: 2f374bb14e10…

Disclaimer: Educational only. Coverage varies by employer group and formulary. Always verify with the plan.

Consult

Curious about trends across plans?

I can walk you through how this policy compares and share data-backed patterns. Short call, straight answers.

Email to start a quick consult What I cover (overview)

No commitments—just a brief conversation to see if it’s helpful.

The Policy Vault

Structured prior authorization and step-therapy criteria for commercial health plans. Built by pharmacists for healthcare professionals.

Disclaimer: Educational use only. Coverage varies by employer group and formulary. Always verify with the plan.

Product

Coverage Directory
Why Policy Vault
Methodology

Company

Contact
Press
Support

© 2025 The Policy Vault. Data sourced from official health plan documents.